An interdisciplinary group of researchers at the University of Wisconsin (UW)-Madison have received nearly $11 million to study the biological processes that promote lung scarring in idiopathic pulmonary fibrosis (IPF). Funding comes from a four-year grant (HT94252410543) provided by the U.S. Department of Defense. The research will be…
News
A Phase 2a clinical trial testing the safety of treatment candidate INS018_055 among idiopathic pulmonary fibrosis (IPF) patients in the U.S. is still seeking participants, while a parallel trial in China has now completed enrollment. That’s according to an update from Insilico Medicine, which developed the oral therapy with…
Imaging with a tracer that homes in on scar-forming fibroblasts may help predict the progression of pulmonary fibrosis in people with interstitial lung disease (ILD), offering doctors a way to gauge who should be monitored more closely or begin preventive treatment. That tracer, a radiolabeled form of the fibroblast…
AGMB-447, an inhaled treatment for idiopathic pulmonary fibrosis (IPF) now being tested in a Phase 1 clinical trial, has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA). The FDA gives this designation to therapies that may improve care for people with rare diseases,…
The U.S. Food and Drug Administration (FDA) has granted its orphan drug designation to Alentis Therapeutics’ antibody-based therapy lixudebart (ALE.F02) for idiopathic pulmonary fibrosis (IPF). Orphan drug designation is given to support the accelerated development of investigational treatments for rare diseases, defined as those affecting fewer than 200,000…
Endeavor BioMedicines’ ENV-101 improved lung function and reversed key signs of lung scarring in people with idiopathic pulmonary fibrosis (IPF), according to data from a completed Phase 2a trial. The results, which also showed the treatment had an acceptable tolerability profile, were presented in a late-breaking oral…
The Pulmonary Fibrosis Foundation (PFF) said its two-year-old patient Community Registry achieved a “significant milestone” in its goal to drive more research and discoveries in pulmonary fibrosis (PF) and interstitial lung diseases (ILDs), reaching its 2,000th participant. The registry opened in July 2022 to provide scientists with…
In the U.K., patients with idiopathic pulmonary fibrosis (IPF) who live in economically deprived neighborhoods have worse survival outcomes than those living in more affluent areas, according to a recent study. The study also found that patients who live farther away from specialty care centers tend to have worse…
Pliant Therapeutics’ bexotegrast reversed the signs of lung scarring, while improving lung function and easing cough severity in people with idiopathic pulmonary fibrosis (IPF), according to top-line data from a small Phase 2a imaging trial. Using positron emission tomography (PET) scans, researchers at Massachusetts General Hospital were able…
LTI-03, an inhaled therapy for idiopathic pulmonary fibrosis (IPF) from Aileron Therapeutics, was able to reduce levels of several proteins known to promote tissue scarring in the first group of patients participating in a Phase 1b trial, data from the trial showed. The trial (NCT05954988) is assessing…
